CUE (Cue Biopharma) Shareholder Yield % : -22.91% (As of Mar. 2026)


CUE Cue Biopharma Inc CUE
59 GF Score
Price $28.33
GF Value $62.36
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Cue Biopharma Shareholder Yield %?

Cue Biopharma CUE -0.28% 59 Shareholder Yield % is -22.91% as of Mar. 2026. GuruFocus rates CUE with a GF Score™ of 59/100 and a GF Value™ of $62.36 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,299 Biotechnology companies, Cue Biopharma ranks worse than 80.68% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Cue Biopharma's Shareholder Yield % was -22.91%.


Cue Biopharma  (NAS:CUE) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Cue Biopharma Shareholder Yield % Related Terms


Cue Biopharma Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for Cue Biopharma's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cue Biopharma Shareholder Yield % Chart

Cue Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shareholder Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.52 -43.07 -8.54 -11.77 -89.50

Cue Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.05 -46.25 -27.16 -89.50 -121.45

CUE vs ALPS, AARD, KLRS: Shareholder Yield % Comparison

For the Biotechnology subindustry, Cue Biopharma's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cue Biopharma Shareholder Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cue Biopharma's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Cue Biopharma's Shareholder Yield % falls into.


CUE
59GF Score
Cue Biopharma Inc CUE
Shareholder Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cue Biopharma Shareholder Yield % Calculation

Cue Biopharma's Shareholder Yield % for the quarter that ended in Mar. 2026 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+-138.52 %+17.07 %
=-121.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of -22.91% mean?
Cue Biopharma (CUE) has a Shareholder Yield % of -22.91% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Cue Biopharma and its competitors. According to the industry distribution chart, Cue Biopharma ranks #1048 out of 1299 companies in the Biotechnology industry, placing it in the top 80.7%.
Is Cue Biopharma's Shareholder Yield % too high?
Cue Biopharma's current Shareholder Yield % is -22.91%. Based on the distribution chart, Cue Biopharma ranks #1048 out of 1299 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cue Biopharma has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cue Biopharma's Shareholder Yield % compare to ALPS and AARD?
According to the Biotechnology industry distribution chart, Cue Biopharma ranks #1048 out of 1299 companies for Shareholder Yield %. This places Cue Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Cue Biopharma and its competitors. Cue Biopharma's current Shareholder Yield % is -22.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cue Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cue Biopharma (CUE) is currently considered Possible Value Trap. The stock's GF Value™ is $62.36, compared to a current price of $28.33 — trading 54.6% below its estimated fair value. The current Shareholder Yield % is -22.91%. Cue Biopharma's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Cue Biopharma (CUE), the current Shareholder Yield % is -22.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cue Biopharma (CUE) Overvalued in 2026?

Based on GuruFocus' analysis, Cue Biopharma stock appears to be undervalued. The current stock price of $28.33 is trading 54.6% below its estimated GF Value™ of $62.36. GuruFocus considers Cue Biopharma to be Possible Value Trap.

Key valuation signals for CUE:

  • Shareholder Yield %: -22.91%
  • GF Value™: $62.36 vs. price of $28.33 (54.6% below fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the CUE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cue Biopharma Business Description

Other Exchanges 1UC0:Germany
Address 40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
59GF Score

Get the complete analysis for CUE

Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.33
Price
$62.36
GF Value